Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$3.87 USD
+0.27 (7.50%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth A Momentum B VGM
Fulcrum Therapeutics, Inc. (FULC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.50 | $15.00 | $2.00 | 80.56% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Fulcrum Therapeutics, Inc. comes to $6.50. The forecasts range from a low of $2.00 to a high of $15.00. The average price target represents an increase of 80.56% from the last closing price of $3.60.
Analyst Price Targets (8 )
Broker Rating
Fulcrum Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 2.63 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on nine recommendations.
Of the eight recommendations deriving the current ABR, two are Strong Buy, representing 25% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 7 | 7 | 7 |
Buy | 0 | 0 | 1 | 1 | 1 |
Hold | 5 | 5 | 0 | 0 | 0 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.63 | 2.63 | 1.44 | 1.44 | 1.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/13/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Hold |
9/13/2024 | Not Identified | Not Identified | Moderate Buy | Hold |
9/12/2024 | Not Identified | Not Identified | Strong Buy | Hold |
9/12/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Hold |
9/12/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Hold |
7/19/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
5/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.63 |
ABR (Last week) | 2.63 |
# of Recs in ABR | 8 |
Average Target Price | $6.50 |
LT Growth Rate | 57.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | -0.40 |
FULC FAQs
Fulcrum Therapeutics, Inc. (FULC) currently has an average brokerage recommendation (ABR) of 2.63 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 8 brokerage firms.
The average price target for Fulcrum Therapeutics, Inc. (FULC) is $6.50. The current on short-term price targets is based on 5 reports.
The forecasts for Fulcrum Therapeutics, Inc. (FULC) range from a low of $2 to a high of $15. The average price target represents a increase of $67.96 from the last closing price of $3.87.
The current UPSIDE for Fulcrum Therapeutics, Inc. (FULC) is 67.96%
Based on short-term price targets offered by eight analysts, the average price target for Fulcrum Therapeutics, Inc. comes to $6.50. The forecasts range from a low of $2.00 to a high of $15.00. The average price target represents an increase of 80.56% from the last closing price of $3.60.